Model 20105 Lead Study
This trial is active, not recruiting.
|Condition||sick sinus node syndrome|
|Start date||November 2014|
|End date||July 2016|
|Trial size||16 participants|
|Trial identifier||NCT02301429, LV DDD|
The purpose of this study is to evaluate the implant procedure and feasibility of a new lead developed to pace and sense the left chambers of the heart.
|United States||No locations recruiting|
|Other Countries||No locations recruiting|
|London, Canada||London Teaching Hospital||no longer recruiting|
|Delft, Netherlands||Reinier de Graaf Hospital||no longer recruiting|
|Singapore, Singapore||NUHCS, National University Hospital||no longer recruiting|
|Johannesburg, South Africa||Milpark hospital||no longer recruiting|
|Endpoint classification||safety study|
|Intervention model||single group assignment|
Receiving the model 20105 Lead
All Implant procedure and lead related adverse events will be collected during the first month post implant and analyzed.
time frame: 1 month
Male or female participants at least 18 years old.
Inclusion Criteria: - Subject has Cardiac pacing indication for sinus node dysfunction (dual chamber pacemaker) - Subject has signed and dated the study-specific informed consent form - Subject is 18 years of age or older - Subject is willing, able and committed to participate in Baseline and Follow-up and study procedures for the full length of the study Exclusion Criteria: - Subject is indicated for BiV pacemaker or ICD - Subject is pacing dependent - Subject has a previous Pacemaker System - Subject has known coronary venous vasculature that is inadequate for lead placement - Subject has unstable angina pectoris or has had an acute myocardial infarction (MI) within the last month - Subject has had a coronary artery bypass graft (CABG) or percutaneous transluminal coronary angioplasty (PTCA) within the past three months - Subject is not in sinus rhythm at implant - Subject has had a heart transplant (patients waiting for heart transplants are allowed in the study) - Subject has known renal insufficiency that would prevent them from receiving an occlusive venogram during the implant procedure - Subject is contraindicated for <1mg dexamethasone acetate - Subject is enrolled in any concurrent drug and/or device study that may confound the results of this study - Subject has a terminal illness and is not expected to survive more than 6 months - Subject is a pregnant woman or woman of childbearing potential not on adequate birth control. - Subject is employed by Medtronic or by the department of any of the investigators or is a close relative of any of the investigators. - Legal incapacity or evidence that a subject cannot understand the purpose and risks of the study - Subject meets exclusion criteria required by local law. - Subject is unable to tolerate an urgent thoracotomy
|Official title||Model 20105 Lead Study|
Call for more information